Researchers from CiQUS and the Institute of Health Research of Santiago de Compostela optimized the available pharmacological treatment for ischemic stroke using biomimetic nanoparticles. Their study, “Lyophilized platelet-derived nanocarrier-based thrombolytic therapy for ischemic stroke,” was recently published in the Journal of Nanobiotechnology (https://doi.org/10.1186/s12951-023-02206-5), focusing on biomimetic nanocarriers to enhance ischemic stroke treatment. By encapsulating rtPA in platelet-derived biomimetic nanoparticles, they protected its activity, increased therapeutic efficacy, and reduced adverse effects. Lyophilization enabled long-term storage, overcoming a major obstacle in drug application and commercialization. This work, part of the PLATMED European project under Euronanomed, involved collaboration with laboratories in France and Canada (https://www.usc.es/ciqus/en/news/un-equipo-do-ciqus-mellora-o-tratamento-do-accidente-cerebrovascular-isquemico).